India, February 04, 2025: Leucine Rich Bio, a pioneering company in the field of microbiome research, has reached a significant milestone by achieving accreditation from the National Accreditation Board for Hospitals & Healthcare Providers (NABH). This prestigious recognition makes Leucine Rich Bio the first Indian microbiome company to meet NABH’s stringent standards of quality and excellence.

Expressing his excitement, Mr. Prabhath Manjappa, Co-Founder and Chief Products Officer of Leucine Rich Bio, stated, “Quality is above all things for us. We are happy that we have met the standards of the National Accreditation Board for Hospitals & Healthcare Providers (NABH) council. Our effort for quality continues.”

Leucine Rich Bio is well-known for its innovation in microbiome research and diagnostics. The company’s flagship product, BugSpeaks, South Asia’s first microbiome testing solution, has revolutionized the way microbiome testing is conducted. BugSpeaks offers a deeper understanding of the human microbiota, enabling the development of personalized health insights and solutions.

The NABH accreditation underscores Leucine Rich Bio’s commitment to maintaining the highest standards of quality in research and product development. NABH, a constituent board of the Quality Council of India (QCI), is recognized globally for its rigorous evaluation process, ensuring healthcare organizations adhere to the highest safety and quality standards.

Leucine Rich Bio’s NABH certification is a testament to its dedication to excellence and innovation. This recognition not only strengthens the company’s reputation as a leader in microbiome research but also sets a benchmark for the Indian microbiome industry. It continues its mission to advance scientific knowledge and improve health outcomes by providing cutting-edge solutions. With NABH accreditation, the company is well-positioned to expand its impact, both in India and globally, fostering innovation and ensuring the highest standards of healthcare and diagnostics.